Corcept Therapeutics (CORT) EBITDA (2010 - 2026)

Corcept Therapeutics has disclosed EBITDA across 17 years of filings, most recently posting -$49.6 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$49.6 million, down 1552.02% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.2 million (down 107.41% YoY), and the FY2025 annual result was $44.8 million, down 67.29% from the prior year.
• EBITDA came in at -$49.6 million for Q1 2026 at Corcept Therapeutics, down from $4.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $46.6 million in Q3 2024 to a low of -$49.6 million in Q1 2026.
• The 5-year median for EBITDA is $26.7 million (2025), against an average of $20.4 million.
• Across the five-year window, EBITDA surged 98.61% in 2024 and tumbled 1552.02% in 2026, its largest moves.
• Corcept Therapeutics' EBITDA stood at $22.5 million in 2022, then surged by 40.76% to $31.7 million in 2023, then fell by 20.23% to $25.3 million in 2024, then sank by 82.24% to $4.5 million in 2025, then plunged by 1205.44% to -$49.6 million in 2026.
• The last three EBITDA figures came in at -$49.6 million (Q1 2026), $4.5 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.